| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
BOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, announced today that it will present translational data for micvotabart pelidotin (MICVO), a first-in-concept antibody-drug conjugate (ADC) that cleaves in the extracellular matrix and targets extradomain-B of fibronectin (EDB+FN), at upcoming medical meetings. Data will be presented at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany (October 17-21, 2025), and at the AACR-NCI-EORTC International Conference in Boston, Massachusetts (October 22-26, 2025).
"The data we are presenting at ESMO and AACR-NCI-EORTC add to the growing body of evidence supporting the clinical development of MICVO, which deploys a distinctive non-cellular targeting strategy with an extracellular-cleaving mechanism that is unique compared to traditional cell surface targeting ADCs that internalize and cleave within the cell," said Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer of Pyxis Oncology. "These translational findings further strengthen MICVO's scientific foundation as we continue to understand the potential it holds in solid tumors, while we advance MICVO in the clinic in our head and neck squamous cell carcinoma (HNSCC) focused expansion cohorts and combination studies."
The poster presentations at the ESMO and AACR-NCI-EORTC meetings provide deeper insights into the pharmacodynamic responses of tumors to MICVO as well as MICVO's unique mechanism of action and its potential to exert anti-tumor activity through three mechanisms: direct tumor cell killing, bystander killing and immunogenic cell death. These translational findings highlight MICVO's effects on tumor microenvironment remodeling and immune activation, further reinforcing the potential benefit of MICVO as both monotherapy and in combination with anti-PD1 therapy. Observations include changes in circulating tumor DNA (ctDNA) tumor fraction (TF) to the vast majority of 37 clinical samples tested. Notably, reduction in ctDNA TF after treatment with MICVO, particularly in HNSCC and at the 5.4 mg/kg dose, support a positive molecular response to MICVO and strengthen rationale for continued development of this tumor type and dose in the monotherapy dose expansion study. Additionally, features observed in nonclinical samples of the stromal architecture detected using digital pathology may correlate with sensitivity to MICVO - a finding that may be unique compared to tumor cell surface targeting ADCs, due to MICVO's targeting of a non-cellular structural component of the extracellular matrix.
Three additional posters will also be presented, including two trial-in-progress posters for ongoing clinical studies of MICVO in monotherapy and in combination with pembrolizumab in HNSCC, as well as previously reported Phase 1 monotherapy dose-escalation data in HNSCC.
Presentation details at ESMO 2025 are listed below (all times in Central European Daylight Time, CEDT):
Additional preclinical and translational results will be presented in six posters at the AACR-NCI-EORTC International Conference in Boston, Massachusetts, held from October 22 to 26, 2025, highlighting MICVO's three-part mechanism of action and tumor microenvironment remodeling, which support ongoing clinical studies.
Posted In: PYXS
